Company Overview: Curis, Inc.

Business Focus

• Curis, Inc. is a biotechnology company specializing in the discovery and development of innovative drug candidates for the treatment of human cancers.
• Main product candidate: emavusertib (CA-4948), an orally available small molecule inhibitor targeting IRAK4 (Interleukin-1 receptor associated kinase 4), a key component in pathways dysregulated in cancers.
• Emavusertib is in clinical development-stage trials for various hematologic malignancies, including AML, non-Hodgkin's lymphoma, and PCNSL.

Current Products and Collaborations

• Emavusertib (CA-4948):

  • Undergoing multiple Phase 1/2 clinical trials:
    • TakeAim Lymphoma: Testing in relapsed/refractory PCNSL combined with ibrutinib.
    • TakeAim Leukemia: Testing in AML and high-risk MDS.
    • AML Triplet Study: Add-on to azacitidine and venetoclax in AML in Europe.
  • Clinical data from trials presented in 2022–2025.
  • Received Orphan Drug Designations in 2024 from US and European regulators for PCNSL.
  • Regulatory discussions with FDA and European authorities on accelerated approval pathways.

• Outlicensed/Partnered Programs:

  • Erivedge (vismodegib): Approved Hedgehog pathway inhibitor for basal cell carcinoma, licensed to Genentech/Roche.
  • Royalties from Erivedge are a major revenue source; paid to Curis Royalty LLC.
  • CA-170: An immune checkpoint program licensed to Aurigene, undergoing Phase 2b/3 trials.

Proprietary Technologies & Patents

• Focus on patenting innovations related to IRAK4 inhibitors, Hedgehog pathway modulators, and immune checkpoint targets.
• Owned or licensed numerous patents expiring between 2025 and 2042.

Revenue & Financials

• 2024 Revenue: Approximately $10.9 million from royalties on Erivedge sales.
• 2024 Net Loss: about $43.4 million.
• Total accumulated deficit: $1.2 billion.
• Cash on hand: $20.0 million as of December 31, 2024.
• Recent financing:
  • Completed a registered direct offering and private placement in March 2025 with net proceeds of $9.0 million.
  • Planned to fund operations into Q4 2025.
• Employees: 34 (as of December 31, 2024), with 22 involved in R&D activities.

Key Strategic and Commercial Information

• No in-house sales or marketing infrastructure; relies on third-party partners for commercialization.
• Development efforts are primarily funded via collaborations, licensing fees, royalties, and equity financings.
• The company has significant financial obligations related to licensing agreements, including milestone and royalty payments.
• Continues to seek additional capital to advance its clinical pipeline and sustain operations.

Summary

Curis, Inc. is a biotech firm primarily focused on developing IRAK4 inhibitors like emavusertib for cancers, with revenue driven mainly by royalties from the approved drug Erivedge licensed to Genentech. It operates with a small team, ongoing clinical development programs, and partnerships, while actively seeking additional funding to support its pipeline.